GHRP-2 vs Teriparatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
GHRP-2
Growth Hormone Releasing Peptide 2 (GHRP-2) is considered one of the most potent GHRPs available. It provides strong GH release with moderate hunger increase compared to GHRP-6.
Full details →Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Side-by-Side Comparison
| Aspect | GHRP-2 | Teriparatide |
|---|---|---|
| Mechanism | Binds to the ghrelin receptor (GHS-R) to stimulate GH release from the pituitary. Also has some direct effects on the hypothalamus. Causes less appetite increase than GHRP-6. | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily. Often stacked with GHRH peptides for enhanced GH release. | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. |
| Administration | Subcutaneous injection on an empty stomach. Can be used at bedtime to enhance natural GH pulse during sleep. | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. |
| Side Effects | Moderate hunger increase, water retention, potential prolactin and cortisol elevation (less than GHRP-6), tingling sensations. | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. |
| Best For |